
A South and Central America Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation
Description
South and Central America Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)
The biopharmaceutical contract manufacturing market in South and Central America is expected to grow from US$ 564.89 million in 2021 to US$ 866.71 million by 2028; it is estimated to register a CAGR of 6.3% from 2021 to 2028.
The contract manufacturing organization (CMO) offers many benefits to pharmaceutical companies, including reducing investments in facilities and drug development costs, thereby improving net cash flow. Outsourcing is cheaper and enhances the efficiency of manufacturing processes. It allows pharmaceutical & biotechnology companies to redirect resources to other areas. In the past few years, the contract manufacturing industry was a niche service market offering more manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the rising number of drug manufacturing failures. Pharmaceutical companies undertook many manufacturing facilities to develop innovative drugs in the past. However, the demand for manufacturing outsourcing has continuously risen to reduce the risk of overcapacities. Moreover, several pharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, further growing reliance on CMOS for manufacturing. Furthermore, the CMOs are vital in providing additional benefits to mitigate the risk of supply shortages by offering various sites for pharmaceutical companies with multisite supply strategies and backup capacities.
South and Central America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast to 2028 (US$ Million)
South and Central America Biopharmaceutical Contract Manufacturing Market Segmentation
South and Central America Biopharmaceutical Contract Manufacturing Market - By Product
Biologics Monoclonal Antibodies Recombinant Proteins Vaccines Others Biosimilar
South and Central America Biopharmaceutical Contract Manufacturing Market - By Service
Process Development Downstream Processing Upstream Processing Fill and Finish Operation Analytical and QC Studies Packaging
South and Central America Biopharmaceutical Contract Manufacturing Market - By Source
Mammalian Microbial-Based Biologics/ Non-Mammalian
South and Central America Biopharmaceutical Contract Manufacturing Market- By Country
Brazil Argentina The Rest of South and Central America South and Central America Biopharmaceutical Contract Manufacturing Market-Companies Mentioned
Abb Vie Inc. Ajinomoto Co. Inc Boehringer Ingelheim International Gmb H General Electric Company Lonza MERCK KGAA Samsung Biologics THERMO FISHER SCIENTIFIC INC
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the SAM Biopharmaceutical Contract Manufacturing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the SAM Biopharmaceutical Contract Manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth SAM market trends and outlook coupled with the factors driving Biopharmaceutical Contract Manufacturing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
The biopharmaceutical contract manufacturing market in South and Central America is expected to grow from US$ 564.89 million in 2021 to US$ 866.71 million by 2028; it is estimated to register a CAGR of 6.3% from 2021 to 2028.
The contract manufacturing organization (CMO) offers many benefits to pharmaceutical companies, including reducing investments in facilities and drug development costs, thereby improving net cash flow. Outsourcing is cheaper and enhances the efficiency of manufacturing processes. It allows pharmaceutical & biotechnology companies to redirect resources to other areas. In the past few years, the contract manufacturing industry was a niche service market offering more manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the rising number of drug manufacturing failures. Pharmaceutical companies undertook many manufacturing facilities to develop innovative drugs in the past. However, the demand for manufacturing outsourcing has continuously risen to reduce the risk of overcapacities. Moreover, several pharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, further growing reliance on CMOS for manufacturing. Furthermore, the CMOs are vital in providing additional benefits to mitigate the risk of supply shortages by offering various sites for pharmaceutical companies with multisite supply strategies and backup capacities.
South and Central America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast to 2028 (US$ Million)
South and Central America Biopharmaceutical Contract Manufacturing Market Segmentation
South and Central America Biopharmaceutical Contract Manufacturing Market - By Product
Biologics Monoclonal Antibodies Recombinant Proteins Vaccines Others Biosimilar
South and Central America Biopharmaceutical Contract Manufacturing Market - By Service
Process Development Downstream Processing Upstream Processing Fill and Finish Operation Analytical and QC Studies Packaging
South and Central America Biopharmaceutical Contract Manufacturing Market - By Source
Mammalian Microbial-Based Biologics/ Non-Mammalian
South and Central America Biopharmaceutical Contract Manufacturing Market- By Country
Brazil Argentina The Rest of South and Central America South and Central America Biopharmaceutical Contract Manufacturing Market-Companies Mentioned
Abb Vie Inc. Ajinomoto Co. Inc Boehringer Ingelheim International Gmb H General Electric Company Lonza MERCK KGAA Samsung Biologics THERMO FISHER SCIENTIFIC INC
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the SAM Biopharmaceutical Contract Manufacturing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the SAM Biopharmaceutical Contract Manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth SAM market trends and outlook coupled with the factors driving Biopharmaceutical Contract Manufacturing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Table of Contents
124 Pages
- 1. Introduction
- 1.1 Study Scope
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 SCAM Biopharmaceutical Contract Manufacturing Market - By Product
- 1.3.2 SCAM Biopharmaceutical Contract Manufacturing Market - By Service
- 1.3.3 SCAM Biopharmaceutical Contract Manufacturing Market - By Source
- 1.3.4 SCAM Biopharmaceutical Contract Manufacturing Market - By Country
- 2. SCAM Biopharmaceutical Contract Manufacturing Market - Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. SCAM Biopharmaceutical Contract Manufacturing - Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 SCAM - PEST Analysis
- 4.3 Expert Opinion
- 5. SCAM Biopharmaceuticals Contract Manufacturing Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Rising Outsourcing by Pharmaceutical Companies
- 5.1.2 Increasing Demand for Biologics
- 5.2 Market Restraints
- 5.2.1 Surge in Competition in Industry
- 5.3 Future Trends
- 5.3.1 Consolidation in Pharmaceutical CMO Industry
- 5.3.2 COVID-19 Pandemic
- 5.4 Impact Analysis
- 6. Biopharmaceutical Contract Manufacturing Market - SCAM Analysis
- 6.1 SCAM Biopharmaceutical Contract Manufacturing Market Revenue Forecast and Analysis
- 7. SCAM Biopharmaceuticals Contract Manufacturing Market Analysis - By Product
- 7.1 Overview
- 7.2 SCAM Biopharmaceuticals Contract Manufacturing Market Revenue Share, by Product (2021 and 2028)
- 7.3 Biologics
- 7.3.1 Overview
- 7.3.2 Biologics: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.1 Monoclonal Antibodies
- 7.3.2.1.1 Overview
- 7.3.2.1.2 Monoclonal Antibodies: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.2 Recombinant Proteins
- 7.3.2.2.1 Overview
- 7.3.2.2.2 Recombinant Proteins: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.3 Vaccines
- 7.3.2.3.1 Overview
- 7.3.2.3.2 Vaccines: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.4 Others
- 7.3.2.4.1 Overview
- 7.3.2.4.2 Others: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4 Biosimilar
- 7.4.1 Overview
- 7.4.2 Biosimilar: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8. SCAM Biopharmaceuticals Contract Manufacturing Market - By Service
- 8.1 Overview
- 8.2 SCAM Biopharmaceuticals Contract Manufacturing Market, by Service, 2021 and 2028 (%)
- 8.3 Process Development
- 8.3.1 Overview
- 8.3.2 Process Development: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.3.2.1 Downstream Processing
- 8.3.2.1.1 Overview
- 8.3.2.1.2 Downstream Processing: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.3.2.2 Upstream Processing
- 8.3.2.2.1 Overview
- 8.3.2.2.2 Upstream Processing: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.4 Fill and Finish Operations
- 8.4.1 Overview
- 8.4.2 Fill and Finish Operations: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.5 Analytical and QC Studies
- 8.5.1 Overview
- 8.5.2 Analytical and QC Studies: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.6 Packaging
- 8.6.1 Overview
- 8.6.2 Packaging: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 9. SCAM Biopharmaceuticals Contract Manufacturing Market - By Source
- 9.1 Overview
- 9.2 SCAM Biopharmaceuticals Contract Manufacturing Market, by Source, 2021 and 2028 (%)
- 9.3 Mammalian
- 9.3.1 Overview
- 9.3.2 Mammalian: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 9.4 Microbial/Non-Mammalian-Based Biologics
- 9.4.1 Overview
- 9.4.2 Microbial/Non-Mammalian-Based Biologics: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 10. SCAM Biopharmaceutical Contract Manufacturing Market - Country Analysis
- 10.1 SCAM: Biopharmaceutical Contract Manufacturing Market
- 10.1.1 Overview
- 10.1.3 SCAM: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
- 10.1.3.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.3.1.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.3.1.2 Brazil: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.1.3.1.2.1 Brazil: Biologics Market, 2019-2028 (USD Million)
- 10.1.3.1.3 Brazil: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.1.3.1.3.1 Brazil: Process Development Market, 2019-2028 (USD Million)
- 10.1.3.1.4 Brazil: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.1.3.2 Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.3.2.1 Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.3.2.2 Argentina: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.1.3.2.2.1 Argentina: Biologics Market, 2019-2028 (USD Million)
- 10.1.3.2.3 Argentina: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.1.3.2.3.1 Argentina: Process Development Market, 2019-2028 (USD Million)
- 10.1.3.2.4 Argentina: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.1.3.3 Rest of SCAM: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.3.3.1 Rest of SCAM: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.3.3.2 Rest of SCAM: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.1.3.3.2.1 Rest of SCAM: Biologics Market, 2019-2028 (USD Million)
- 10.1.3.3.3 Rest of SCAM: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.1.3.3.3.1 Rest of SCAM: Process Development Market, 2019-2028 (USD Million)
- 10.1.3.3.4 Rest of SCAM: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 11. Biopharmaceutical Contract Manufacturing Market - Industry Landscape
- 11.1 Overview
- 11.2 Organic Developments
- 11.2.1 Overview
- 11.3 Inorganic Developments
- 11.3.1 Overview
- 12. Company Profiles
- 12.1 Boehringer Ingelheim International GmbH
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 THERMO FISHER SCIENTIFIC INC.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 General Electric Company
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 MERCK KGAA
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Lonza
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Samsung Biologics
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 AbbVie Inc.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Ajinomoto Co. Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms
- List of Tables
- Table 1. SCAM Biopharmaceutical Contract Manufacturing Market -Revenue and Forecast to 2028 (US$ Million)
- Table 2. Brazil Biopharmaceutical Contract Manufacturing Market, by Product- Revenue and Forecast to 2028 (USD Million)
- Table 3. Brazil Biologics Market - Revenue and Forecast to 2028 (USD Million)
- Table 4. Brazil Biopharmaceutical Contract Manufacturing Market, by Service - Revenue and Forecast to 2028 (USD Million)
- Table 5. Brazil Process Development Market - Revenue and Forecast to 2028 (USD Million)
- Table 6. Brazil Biopharmaceutical Contract Manufacturing Market, by Source - Revenue and Forecast to 2028 (USD Million)
- Table 7. Argentina Biopharmaceutical Contract Manufacturing Market, by Product- Revenue and Forecast to 2028 (USD Million)
- Table 8. Argentina Biologics Market - Revenue and Forecast to 2028 (USD Million)
- Table 9. Argentina Biopharmaceutical Contract Manufacturing Market, by Service - Revenue and Forecast to 2028 (USD Million)
- Table 10. Argentina Process Development Market - Revenue and Forecast to 2028 (USD Million)
- Table 11. Argentina Biopharmaceutical Contract Manufacturing Market, by Source - Revenue and Forecast to 2028 (USD Million)
- Table 12. Rest of SCAM Biopharmaceutical Contract Manufacturing Market, by Product- Revenue and Forecast to 2028 (USD Million)
- Table 13. Rest of SCAM Biologics Market - Revenue and Forecast to 2028 (USD Million)
- Table 14. Rest of SCAM Biopharmaceutical Contract Manufacturing Market, by Service - Revenue and Forecast to 2028 (USD Million)
- Table 15. Rest of SCAM Process Development Market - Revenue and Forecast to 2028 (USD Million)
- Table 16. Rest of SCAM Biopharmaceutical Contract Manufacturing Market, by Source - Revenue and Forecast to 2028 (USD Million)
- Table 17. Organic Developments Done By Companies
- Table 18. Inorganic Developments Done By Companies
- Table 19. Glossary of Terms, SCAM Biopharmaceutical Contract Manufacturing Market
- List of Figures
- Figure 1. SCAM Biopharmaceutical Contract Manufacturing Market Segmentation
- Figure 2. SCAM Biopharmaceutical Contract Manufacturing Segmentation, By Country
- Figure 3. SCAM Biopharmaceutical Contract Manufacturing Market Overview
- Figure 4. Biologics Segment Held Largest Share Of Product In SCAM Biopharmaceutical Contract Manufacturing Market
- Figure 5. Brazil Is Expected to Show Remarkable Growth During the Forecast Period
- Figure 6. SCAM PEST Analysis
- Figure 7. SCAM Biopharmaceutical Contract Manufacturing Market Impact Analysis of Drivers and Restraints
- Figure 8. SCAM Biopharmaceutical Contract Manufacturing Market - Revenue Forecast and Analysis - 2020 - 2028
- Figure 9. SCAM Biopharmaceuticals Contract Manufacturing Market Revenue Share, by Product (2021 and 2028)
- Figure 10. Biologics: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 11. Monoclonal Antibodies: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 12. Recombinant Proteins: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 13. Vaccines: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 14. Others: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 15. Biosimilar: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 16. SCAM Biopharmaceuticals Contract Manufacturing Market, by Service, 2021 and 2028 (%)
- Figure 17. Process Development: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 18. Downstream Processing: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 19. Upstream Processing: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 20. Fill and Finish Operations: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 21. Analytical and QC Studies: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 22. Packaging: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 23. SCAM Biopharmaceuticals Contract Manufacturing Market, by Source, 2021 and 2028 (%)
- Figure 24. Mammalian: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 25. Microbial/Non-Mammalian-Based Biologics: SCAM Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 26. SCAM: Biopharmaceutical Contract Manufacturing Market, by Key Country - Revenue (2021) (USD Million)
- Figure 27. SCAM: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
- Figure 28. Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- Figure 29. Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- Figure 30. Rest of SCAM: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.